FindTrial
Sign In

durvalumab + tremelimumab

COMBINATION_PRODUCT4 trials

Sponsors

Centre Leon Berard, Seoul National University Hospital, Yonsei University, Universitaire Ziekenhuizen KU Leuven

Conditions

Durvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLCHypopharynxLarynxMalignant Solid NeoplasmsOral Cavity Squamous Cell CarcinomaOropharynxStage II-IVB Operable HNSCC Oral Cavity

Phase 1

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity
Active, not recruitingNCT03784066
Universitaire Ziekenhuizen KU LeuvenOral Cavity Squamous Cell Carcinoma
Start: 2018-08-27End: 2026-03-24Updated: 2024-07-03

Phase 2

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
RecruitingNCT02029001
Centre Leon BerardMalignant Solid Neoplasms
Start: 2014-03-31End: 2027-10-31Target: 900Updated: 2025-08-07
Pulmonary sarcomatoid_MEDI4736+Treme
CompletedNCT03022500
Seoul National University HospitalDurvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC
Start: 2017-05-18End: 2019-11-30Updated: 2024-05-29
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
NCT03737968
Yonsei UniversityHypopharynx, Larynx, Oropharynx +1
Start: 2019-01-02End: 2023-10-31Updated: 2023-03-21

Related Papers

Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.
2026-01-11
4-1BB<sup>+</sup> Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy.
2025-10-031 citations
Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes
Journal for ImmunoTherapy of Cancer2024-06-0120 citations
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Cancers2023-06-302 citations
Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.
Journal of Clinical Oncology2023-06-011 citations
Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology2023-06-01
Durvalumab + tremelimumab in biologically selected advanced/metastatic solid tumors.
Journal of Clinical Oncology2023-06-01
Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): Updated results with high dimensional profiling of circulating immune cells.
Journal of Clinical Oncology2022-06-012 citations
Interim analysis for window of opportunity trial of single dose preoperative durvalumab (D) with or without tremelimumab (T) for operable head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology2021-05-205 citations
Correlation between an automated functional assay that predicts targeted agent (TA) sensitivity and the tumor response of the sorafenib treatment evaluated within the MOST clinical trial
Annals of Oncology2018-09-01
MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.
Journal of Clinical Oncology2016-05-202 citations
A randomized, open-label, Phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors.
Journal of Clinical Oncology2015-05-201 citations